BioPharmSignal logoBioPharmSignal

Biotech News

SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics

Y-mAbs (YMAB)Y-mAbsCompany update

West Conshohocken, PA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc.

Related news

GSKGSK plc2026-07-15 13:40 EST

GSK completes acquisition of Nuvalent, Inc.

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

View all latest news

Y-mAbs

Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.

Recent company news

YMABY-mAbs2025-09-16 12:41 EST

SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics

YMABY-mAbs2025-08-08 10:35 EST

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

YMABY-mAbs2025-08-07 11:30 EST

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

YMABY-mAbs2025-08-05 12:30 EST

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

YMABY-mAbs2025-05-28 10:35 EST

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States